Abstract: The present invention relates generally to a method of identifying a subject having an increased risk of developing cervical cancer based on levels of IGF-II in serum and levels of EGF-R and HPV-E6/E7 in cervical epithelial cells and in serum.
Type:
Grant
Filed:
January 29, 2001
Date of Patent:
May 10, 2005
Assignee:
MUSC Foundation for Research Development
Abstract: A compound having the formula (I) wherein the substituents are defined herein. Also provided are pharmaceutical compositions including a compound of formula (I) in a pharmaceutical carrier, for treating a disease caused by a picornavirus. Also provided is a method of treating a subject with a disease caused by a picornavirus, including a compound of formula (I) in a pharmaceutical carrier.
Type:
Grant
Filed:
June 15, 1997
Date of Patent:
May 3, 2005
Assignee:
Cytoclonal Pharmaceutics, Inc.
Inventors:
Dorit Arad, Yuval Elias, Orna Elhanany, Michael Shokhen, Leopold Puzis
Abstract: The present invention pertains to methods for therapeutic and prophylactic treatment of cats against FIV infection. Methods of the present invention utilize a combination of antiretroviral compounds to treat or prevent FIV infection in a feline animal. In one embodiment, the method comprises administering an effective amount of AZT and another nucleoside analog, such as, for example, 3TC to the animal. In another embodiment, cats are given an effective dose(s) of AZT, 3TC, and a retroviral protease inhibitor.
Type:
Grant
Filed:
May 28, 1999
Date of Patent:
April 5, 2005
Inventors:
Ben M. Dunn, Janet K. Yamamoto, Maki Arai
Abstract: The present invention relates to full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP, novel members of the hyaluronan receptor family. The invention provides isolated nucleic acid molecules encoding human to full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP receptors. Full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP receptor activity. Also provided are diagnostic methods for detecting disease states related to the aberrant expression of full-length WF-HABP, WF-HABP, OE-HABP, and BM-HABP receptors.
Type:
Grant
Filed:
December 20, 1999
Date of Patent:
March 29, 2005
Assignees:
Human Genome Sciences, Inc., The American Red Cross
Inventors:
Gregg A. Hastings, Gene Liau, Elena Tsifrina
Abstract: Peptide analogs the high molecular weight kininogen domain 3 are potent inhibitors of angiogenesis. The peptides have the formula (a) X1-Asn-Asn-Ala-Thr-Phe-Tyr-Phe-Lys-X2, (b) X3-Cys-Val-Gly-Cys-X4, (c) X5-Leu-Asp-X7-Asn-Ala-Glu-Val-Tyr-X6, or (d) Tyr-Phe-Ile-Asp-Phe-Val-Ala-Arg-Glu-Thr-Thr-X7-Ser-Lys-Glu-Ser wherein: X1, X2, X3, X4, X5, and X6 are from zero to twelve amino acids, independently the same or different, more preferably from zero to six amino acids, and; X7 is Ala or Cys. The peptides may also comprise biologically active fragments of high molecular weight kininogen domain 3. Methods of inhibiting endothelial cell proliferation and angiogenesis are provided.
Type:
Grant
Filed:
December 15, 1999
Date of Patent:
March 22, 2005
Assignee:
Temple University - Of The Commonwealth System of Higher Education
Abstract: Benzimidazole derivatives and salts and prodrugs thereof are disclosed, together with methods for the treatment of cancers or viral infections in warm blooded animals by administration of these compounds. Such compounds may be used in combination with a chemotherapeutic agent and/or a potentiator.
Type:
Grant
Filed:
September 29, 2000
Date of Patent:
March 8, 2005
Assignee:
UAF Technologies and Research, LLC
Inventors:
James Berger Camden, James Clarence Quada, Jr., Joseph K. Agyin
Abstract: The present invention is directed to isolated active fragments of a hypersensitive response elicitor protein or polypeptide which fragment does not elicit a hypersensitive response in plants. Also disclosed are isolated DNA molecules which encode such fragments. Isolated fragments of hypersensitive response elicitor proteins or polypeptides in accordance with the present invention and the isolated DNA molecules that encode them have the following activities: imparting disease resistance to plants, enhancing plant growth, and/or controlling insects on plants. This can be achieved by applying the fragments of a hypersensitive response elicitor in a non-infectious form to plants or plant seeds under conditions effective to impart disease resistance, to enhance plant growth, and/or to control insects on plants or plants grown from the plant seeds.
Type:
Grant
Filed:
October 4, 1999
Date of Patent:
February 22, 2005
Assignees:
EDEN Bioscience Corporation, Cornell Research Foundation, Inc.
Inventors:
Zhong-Min Wei, Hao Fan, Jennifer J. Stephens, Steven V. Beer, Ron J. Laby
Abstract: A fragment condensation process for the synthesis of analogs of parathyroid hormone (PTH) and parathyroid hormone related peptide (PTHrP), in which amino acid residues (22-31) form a synthetic amphipathic ?-helix, is provided.
Abstract: Methods for treating a patient for insulin resistance to decrease the insulin resistance in a patient having Metabolic Syndrome comprising Primary Insulin Resistance and abdominal/visceral obesity comprise administering to the patient growth hormone or a functional derivative thereof in an amount effective for decreasing insulin resistance of the patient.
Type:
Grant
Filed:
March 31, 1998
Date of Patent:
January 25, 2005
Assignee:
Pharmacia AB
Inventors:
Gudmundur Johannsson, Per Mårin, Lars Lönn, Malin Ottosson, Kaj Stenlöf, Per Björntorp, Lars Sjöström, Bengt-Åke Bengtsson
Abstract: Disclosed is an extract from Korean mistletoe KM-110, which is of immunity enhancement and activity against tumor metastasis and can be used as an adjuvant material for vaccines applicable for the induction of humoral and cell-mediated immunity. Also disclosed are its fractions, a protein fraction KM-AS, a lectin fraction KML-C, lectin components KML-IIU and KML-IIL, which both are further purified from lectin fraction KML-C, a protein KMHBP which is obtained through heparin binding chromatography eluting with NaCl from a fraction C-free AS which is a portion of the KM-AS free of KML-C, and a mixture KM of the KMHBP and the KML-C. They are revealed as to their roles in the humoral and cell-mediated immunity enhancement and antitumoral activity.
Abstract: A therapeutic composition comprising an alkyl, aralkyl, alkoxyalkyl or carboxyalkyl ester of 2-ketoalkanoic acid and a component for inducing and stabilizing the enol resonance form of the ester at physiological pH values is disclosed. The composition of the invention further comprises a pharmceutically acceptable carier vehicle in which the enol resonance form of the ester is stabilized at physiological pH values. Formulations containing the compositions of the invention permit the successful use of 2-ketoalkanoic acid esters, e.g., pyruvic acid esters, to treat, e.g., ischemic events, shock, organ reanimation, resuscitation and other recognized pyruvate-effective treatments. The compositions of the inventions are also useful in a process for preserving organ parts, organs or limbs removed from a living mammal and in need of preservation, e.g., for later transplantation to an organ recipient.
Type:
Grant
Filed:
April 4, 2002
Date of Patent:
January 25, 2005
Assignees:
Beth Israel Deconess Medical Center, Inc., Xanthus Life Sciences, Inc.
Inventors:
Alfred M. Ajami, Carrie A. Sims, Mitchell P. Fink
Abstract: The present invention discloses novel imidazolidinones which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such imidazolidinones as well as methods of using them to treat disorders associated with the HCV protease.
Type:
Grant
Filed:
July 19, 2001
Date of Patent:
January 4, 2005
Assignee:
Schering Corporation
Inventors:
Ashok Arasappan, Tejal Parekh, F. George Njoroge, Viyyoor Moopil Girijavallabhan, Ashit K. Ganguly
Abstract: Surfactant protein D (SP-D) is a 43-kDa member of the collectin family of collagenous lectin domain-containing proteins that is expressed in epithelial cells of the lung. The SP-D gene was targeted by homologous recombination in embryonic stem cells that were used to produce SP-D (?/?) mice. The SP-D (?/?) deficiency caused inflammation, increased oxidant production by isolated alveolar macrophages, abnormal surfactant structure and levels, and decreased SP-A expression. Therefore, disclosed is the SP-D (?/?) mouse as an excellent model for emphysema. Also included are models for testing emphysema therapies in the mouse model, methods for using SP-D protein or DNA as a treatment for emphysema and pulmonary infections, and diagnosis.
Abstract: The present invention is directed to novel chimpanzee erythropoietin polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, and antibodies which bind to the polypeptides of the present invention.
Abstract: Methods for recovering factor VIII/vWF-complex that involve binding factor VIII/vWF-complex from a protein solution to a cation exchanger and recovering factor VIII/vWF-complex by step-wise elution are disclosed. The recovered complex contains high-molecular vWF multimers. Compositions containing factor VIII/vWF-complex as purified by cation exchange chromatography are also provided.
Type:
Grant
Filed:
May 8, 2000
Date of Patent:
December 14, 2004
Assignee:
Baxter Aktiengesellschaft
Inventors:
Artur Mitterer, Bernhard Fischer, Öyvind L. Schönberger, Kathrin Thomas-Urban, Friedrich Dorner, Johann Eibl
Abstract: The present invention features methods for purifying polypeptides of interest using a modified Fluorescein arsenical helix binder (FlAsH) compound immobilized on a solid support. An exemplary FlAsH target sequence motif is also presented. Examples of modification of the FlAsH compound which allow immobilization to a solid support are also provided. The present invention also provides DNA constructs for producing a dual affinity tagged polypeptide and methods for purification thereof.
Type:
Grant
Filed:
February 11, 2000
Date of Patent:
December 14, 2004
Assignee:
The Regents of the University of California
Inventors:
Ronald D. Vale, Kurt Thorn, Roger Cooke, Marija Matsuka, Nariman Naber
Abstract: The present invention relates to an agent comprising a neurotoxin, methods for making the agents and methods for treating endocrine disorders, for example gonadotrophin related illnesses. Preferably, the agent comprises at least a portion of a botulinum toxin.
Abstract: An inhibitory compound having the structure: Group I-Group II. Group I has the structure:
where H represents a hydrogen; C represents a carbon; O represents an oxygen; N represents a nitrogen; each R, independently, is chosen from the group consisting of the R groups of an amino acid, including proline; each broken line, independently, represents a bond to an H or a bond to one R group, and each H′ represents that bond or a hydrogen; and p is an integer between 0 and 4 inclusive. Alternatively Group I has the structure:
where n is between 0 and 3 inclusive, each G2 and G3 independently is H or C1-3 (one to three carbon atoms) alkyl, G1 is NH3 (H3 represents three hydrogens),
(H2 represents two hydrogens), or
where G5 and G6 can be NH, H, or C1-3 alkyl or alkenyl with one or more carbons substituted with a nitrogen. G1 bears a charge, and G1 and Group II do not form a covalently bonded ring structure at pH 7.0.
Type:
Grant
Filed:
October 15, 1997
Date of Patent:
November 30, 2004
Assignee:
Trustees of Tufts College
Inventors:
William W. Bachovchin, Andrew G. Plaut, George R. Flentke
Abstract: The present invention relates to novel cyclic or constrained acyclic compounds which modulate the activity of G protein-coupled receptors and are useful in the treatment of conditions mediated by G protein-coupled receptors, for example, inflammatory conditions.
Type:
Grant
Filed:
April 21, 2000
Date of Patent:
November 23, 2004
Assignee:
The University of Queensland
Inventors:
David Fairlie, Stephen Maxwell Taylor, Angela Monique Finch, Allan Wong
Abstract: Peptides of Dendroaspis, including chimeric peptides thereof, are provided, as well as methods of using the peptides as natriuretics, diuretics, and/or vasodilators.
Type:
Grant
Filed:
March 26, 2002
Date of Patent:
November 16, 2004
Assignee:
Mayo Foundation for Medical Education and Research